Drug Type Gene therapy |
Synonyms Angiogenic-gene-therapy(ID-Pharma), Recombinant SeV-hFGF2/dF, SeV-hFGF2/dF + [8] |
Target |
Action inducers |
Mechanism FGF2 gene transference, Angiogenesis inducers |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Occlusion of artery | Phase 3 | China | 10 Sep 2018 | |
Chronic Limb-Threatening Ischemia | Phase 3 | China | 05 Sep 2018 | |
Peripheral arterial occlusive disease | Phase 3 | China | 05 Sep 2018 | |
Intermittent Claudication | Phase 2 | Japan | 01 Oct 2014 | |
Peripheral Arterial Disease | Phase 2 | Japan | 15 Jan 2013 | |
Perioperative ischaemia | Phase 2 | - | - | |
Perioperative ischaemia | Phase 2 | - | - |
Phase 1/2 | 27 | ozwppsycxg(gvhxeevmtr) = mtfxalkckk xywlrvwezz (sehyzamfui ) View more | Positive | 22 Apr 2019 | |||
NCT02276937 (Pubmed) Manual | Phase 1/2 | 12 | (xgthzssigh) = None vldsepvjvq (ykitkexhdj ) View more | Positive | 15 Jan 2013 |